Clinical trial investigates Dapagliflozin for COVID-19 treat
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
Phase III clinical trial of diabetes drug Farxiga (dapagliflozin) has been started to treat hospitalised Covid-19 patients at risk of serious complications by AstraZeneca

Farxiga: sodium-glucose transport protein 2 (SGLT2) inhibitor for adults with insufficiently controlled type 2 diabetes (T2D). Reduces weight and blood pressure.

Data from the DECLARE CV outcomes trial in adult T2D patients showed that Farxiga decreased the risk of heart failure or cardiovascular (CV) death.

New randomized, global DARE-19 Trial has 900 patients enrolled with a history of hypertension (HTN), atherosclerotic CV disease, heart failure with reduced or preserved ejection fraction, T2D, or CKD Stage III to IV.

Will evaluate the drug’s ability to reduce the risk of disease progression, clinical complications, and death from Covid-19 in patients with CV, metabolic, or kidney risk factors.

Presence of CV, metabolic, or kidney conditions, linked to poor outcomes & death in Covid-19 patients.

The trial is based on Farxiga’s protective effect in heart failure patients with decreased ejection fraction (HFrEF), chronic kidney disease (CKD), or T2D.

The primary outcome is time to the first occurrence of death due to any cause or new/worsened organ dysfunction during 30 days of follow-up.

Source: https://www.clinicaltrialsarena.com/news/astrazeneca-farxiga-covid-19-trial/
Dr. F●●●y P●●●●●l and 16 others like this5 shares
Like
Comment
Share